Prosecution Insights
Prosecution Insights
47 pending office actions • 19 art units • 40 examiners • 0 of 47 (0%) have an AI response strategy ready • 36 patents granted in the last 365 days
Based on the USPTO statutory response window for each pending office action. 15 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Every pending office action with a known statutory deadline, placed on a days-until-due axis. Dots left of Today are overdue; the further right, the more runway. Cases that share a deadline window stack vertically. 15 of the docket's apps have a known mailing date.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 only | 1 (2%) |
| §101 + other | 3 (6%) |
| §103 only | 13 (28%) |
| §102 only | 1 (2%) |
| §112 only | 4 (9%) |
| Double-patenting only | 5 (11%) |
| Double-patenting + other | 11 (23%) |
| Multi-statute (no §101) | 9 (19%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| DUFFY, BRADLEY | 3 | 54.6% | +45.5% |
| SANG, HONG | 3 | 54.7% | +62.6% |
| SULLIVAN, DENNIS JOHN | 3 | 61.1% | +47.4% |
| BERHANE, SELAM | 2 | 59.0% | +55.8% |
| IVICH, FERNANDO NMN | 1 | 45.7% | +72.7% |
| ROSENTHAL, ANDREW S | 1 | 51.4% | +40.2% |
| PETRASH, HILARY ANN | 1 | 63.9% | +53.5% |
| WEIDNER, ADAM M | 1 | 63.6% | +34.2% |
| POPA, ILEANA | 1 | 21.4% | +14.6% |
| OGUNTADE, ELIZABETH BISOLA | 1 | 0.0% | +0.0% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 8 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17235974 | NEUROLOGIC TOXICITY ASSESSMENT METHODS AND SYSTEMS FOR DOCUMENTING CHANGES IN HANDWRITING | ROBERTS, ANNA L | 164d overdue |
| 17825244 | ANTI-IDIOTYPIC ANTIBODIES AGAINST ANTI-CD79B ANTIBODIES | GUSTILO, ESTELLA M | 147d overdue |
| 18143749 | Use of Anti-EGFR/Anti-Met Antibody to Treat Liver Cancer | MOSELEY II, NELSON B | 6d |
| 17005858 | B-CELL MATURATION COMPLEX CAR T CONSTRUCT AND PRIMERS | HANEY, AMANDA MARIE | 23d |
| 18552504 | ANTI-TAU ANTIBODIES AND USES THEREOF | XIAO, YAN | 28d |
| 17182429 | CAPACITY OPTIMIZATION ACROSS DISTRIBUTED MANUFACTURING SYSTEMS | LEE, PO HAN | 34d |
| 19418900 | METHODS OF TREATING HIGH RISK MULTIPLE MYELOMA | SANG, HONG | — |
| 19281154 | METHODS AND COMPOSITIONS FOR MONITORING THE TREATMENT OF RELAPSED AND/OR REFRACTORY MULTIPLE MYELOMA | IVICH, FERNANDO NMN | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 8 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18175345 | Methods of Treating High Risk Multiple Myeloma | SANG, HONG | 10d overdue |
| 16797301 | Methods of Treating Newly Diagnosed Multiple Myeloma with a Combination of An Antibody that Specifically Binds CD38, Lenalidomide and Dexamethasone | SANG, HONG | 4d overdue |
| 18216026 | Use of Anti-EGFR/Anti-Met Antibody to Treat Gastric or Esophageal Cancer | SULLIVAN, DENNIS JOHN | 54d |
| 19637933 | Subcutaneous Formulations Of Anti-CD38 Antibodies And Their Uses | DUFFY, BRADLEY | — |
| 19637868 | Subcutaneous Formulations Of Anti-CD38 Antibodies And Their Uses | DUFFY, BRADLEY | — |
| 19563621 | Subcutaneous Formulations Of Anti-CD38 Antibodies And Their Uses | DUFFY, BRADLEY | — |
| 19418900 | METHODS OF TREATING HIGH RISK MULTIPLE MYELOMA | SANG, HONG | — |
| 19281154 | METHODS AND COMPOSITIONS FOR MONITORING THE TREATMENT OF RELAPSED AND/OR REFRACTORY MULTIPLE MYELOMA | IVICH, FERNANDO NMN | — |
| Art Unit | Apps |
|---|---|
| 1646 | 6 |
| 1643 | 5 |
| 1674 | 5 |
| 1642 | 5 |
| 1641 | 3 |
| 1675 | 3 |
| 1600 | 3 |
| 1644 | 2 |
| 1678 | 1 |
| 1633 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 19637933 | Subcutaneous Formulations Of Anti-CD38 Antibodies And Their Uses | DUFFY, BRADLEY | 1643 | §102§103DP | Non-Final OA | — | Pending | Apr 02, 2026 |
| 19637868 | Subcutaneous Formulations Of Anti-CD38 Antibodies And Their Uses | DUFFY, BRADLEY | 1643 | §103DP | Non-Final OA | — | Pending | Apr 02, 2026 |
| 19563621 | Subcutaneous Formulations Of Anti-CD38 Antibodies And Their Uses | DUFFY, BRADLEY | 1643 | §102§112DP | Non-Final OA | — | Pending | Mar 11, 2026 |
| 19418900 | METHODS OF TREATING HIGH RISK MULTIPLE MYELOMA | SANG, HONG | 1646 | §102§103§112 | Final Rejection | — | Pending | Dec 12, 2025 |
| 19281154 | METHODS AND COMPOSITIONS FOR MONITORING THE TREATMENT OF RELAPSED AND/OR REFRACTORY MULTIPLE MYELOMA | IVICH, FERNANDO NMN | 1678 | §101§102§103§112Other | Non-Final OA | — | Pending | Jul 25, 2025 |
| 18939761 | PHARMACEUTICAL COMPOSITION FOR ORAL ADMINISTRATION COMPRISING AMINOPYRIMIDINE DERIVATIVE OR PHARMACEUTICALLY ACCEPTABLE SALT, HYDRATE, OR SOLVATE THEREOF | ROSENTHAL, ANDREW S | — | §103DP | Non-Final OA | — | Pending | Nov 07, 2024 |
| 18765663 | Methods of Treating Crohn's Disease with Anti-IL23 Specific Antibody | PETRASH, HILARY ANN | 1644 | §102§112DP | Non-Final OA | — | Pending | Jul 08, 2024 |
| 18691254 | CD33 x Vd2 MULTISPECIFIC ANTIBODIES FOR THE TREATMENT OF CANCER | WEIDNER, ADAM M | — | §112DP | Non-Final OA | — | Pending | Mar 12, 2024 |
| 18583364 | Neoantigens Expressed In Ovarian Cancer And Their Uses | POPA, ILEANA | 1633 | §103 | Non-Final OA | — | Pending | Feb 21, 2024 |
| 18572451 | MATERIALS AND METHODS FOR ENHANCED DETECTION AND SCREENING OF MOLECULES OF THERAPEUTIC POTENTIAL | OGUNTADE, ELIZABETH BISOLA | — | §103§112Other | Non-Final OA | — | Pending | Dec 20, 2023 |
| 18528157 | ANTI- GPRC5D ANTIBODIES, BISPECIFIC ANTIGEN BINDING MOLECULES THAT BIND GPRC5D AND CD3, AND USES THEREOF | NATARAJAN, MEERA | — | §112DP | Non-Final OA | — | Pending | Dec 04, 2023 |
| 18558859 | UNIVERSAL RETARGETING OF ONCOLYTIC HSV | GRABER, JAMES J | 1631 | §103§112 | Non-Final OA | — | Pending | Nov 03, 2023 |
| 18559029 | Device and Method for Sorting Biological Cells | MUTREJA, JYOTI NAGPAUL | 1798 | §102 | Non-Final OA | — | Pending | Nov 03, 2023 |
| 18499523 | ANTI-TNF ANTIBODIES, COMPOSITIONS, AND METHODS FOR THE TREATMENT OF ACTIVE ANKYLOSING SPONDYLITIS | CHANDRA, GYAN | 1674 | §102§103 | Non-Final OA | — | Pending | Nov 01, 2023 |
| 18499720 | BCMA-TARGETED CAR-T CELL THERAPY OF MULTIPLE MYELOMA | HUYNH, PHUONG N | 1641 | DP | Non-Final OA | — | Pending | Nov 01, 2023 |
| 18287742 | MATERIALS AND METHODS FOR IMPROVED PHOSPHOTRANSFERASES | KOROTCHKINA, LIOUBOV G | 1653 | §103§112 | Non-Final OA | — | Pending | Oct 20, 2023 |
| 18284586 | MATERIALS AND METHODS FOR IMMUNE EFFECTOR CELLS REDIRECTION | JUEDES, AMY E | 1644 | §102§112DP | Non-Final OA | — | Pending | Sep 28, 2023 |
| 18552504 | ANTI-TAU ANTIBODIES AND USES THEREOF | XIAO, YAN | 1642 | §102§112Other | Final Rejection | 28d | Pending | Sep 26, 2023 |
| 18549665 | USES OF CD79B ANTIBODIES FOR AUTOIMMUNE THERAPEUTIC APPLICATIONS | HADDAD, MAHER M | 1641 | §112 | Final Rejection | 19d | Pending | Sep 08, 2023 |
| 18461191 | MATERIALS AND METHODS FOR IMPROVED SINGLE CHAIN VARIABLE FRAGMENTS | PUTTLITZ, KARL J | 1646 | §103§112DP | Non-Final OA | — | Pending | Sep 05, 2023 |
| 18222093 | Dosing Regimen for Therapies Comprising Bispecific Anti-EGFR/C-Met Antibodies | DONOGHUE, BRITTNEY ERIN | 1675 | §103§112DP | Non-Final OA | — | Pending | Jul 14, 2023 |
| 18344973 | MATERIALS AND METHODS FOR BIOENGINEERED IPSC POPULATIONS | CANDELARIA, JULIANA IRENE | 1634 | §103 | Final Rejection | 21d | Pending | Jun 30, 2023 |
| 18216026 | Use of Anti-EGFR/Anti-Met Antibody to Treat Gastric or Esophageal Cancer | SULLIVAN, DENNIS JOHN | 1642 | §103Other | Non-Final OA | 54d | Pending | Jun 29, 2023 |
| 18210885 | Safe and Effective Method of Treating Ulcerative Colitis with Anti-IL12/IL23 Antibody | BRISTOL, LYNN ANNE | 1643 | §103Other | Non-Final OA | — | Pending | Jun 16, 2023 |
| 18201516 | High Concentration Bispecific Antibody Formulations | BERHANE, SELAM | 1675 | §103§112DP | Final Rejection | — | Pending | May 24, 2023 |
| 18143749 | Use of Anti-EGFR/Anti-Met Antibody to Treat Liver Cancer | MOSELEY II, NELSON B | 1642 | §102§103Other | Non-Final OA | 6d | Pending | May 05, 2023 |
| 18249807 | PROTEINS COMPRISING DELTA-LIKE LIGAND 3 (DLL3) ANTIGEN BINDING DOMAINS AND THEIR USES | LI, RUIXIANG | 1674 | §112 | Non-Final OA | — | Pending | Apr 20, 2023 |
| 18300683 | Clinically Proven Subcutaneous Pharmaceutical Compositions Comprising Anti-CD38 Antibodies and Their Uses in Combination with Pomalidomide and Dexamethasone | SULLIVAN, DENNIS JOHN | 1642 | §103 | Final Rejection | — | Pending | Apr 14, 2023 |
| 18300288 | Clinically Proven Subcutaneous Pharmaceutical Compositions Comprising Anti-CD38 Antibodies and Their Uses in Combination with Bortezomib and Dexamethasone | SULLIVAN, DENNIS JOHN | 1642 | DP | Non-Final OA | — | Pending | Apr 13, 2023 |
| 18175345 | Methods of Treating High Risk Multiple Myeloma | SANG, HONG | 1646 | §112Other | Non-Final OA | 10d overdue | Pending | Feb 27, 2023 |
| 18080639 | VACCINES BASED ON MUTANT CALR AND JAK2 AND THEIR USES | BARRERA, IMMACULADA | 1671 | DP | Final Rejection | 74d overdue | Pending | Dec 13, 2022 |
| 17992369 | Method of Treating Ulcerative Colitis with Anti-IL23 Specific Antibody | HOWARD, ZACHARY C | 1674 | §101§102§103§112Other | Final Rejection | — | Pending | Nov 22, 2022 |
| 18053904 | STABLE FORMULATIONS COMPRISING A BISPECIFIC BCMA/CD3 ANTIBODY | DUNN, LINDSAY MICHELLE | 1600 | §103 | Non-Final OA | — | Pending | Nov 09, 2022 |
| 17860453 | Manufacturing Methods for Producing Anti-IL12/IL23 Antibody Compositions | PAK, MICHAEL D | 1674 | §112 | Non-Final OA | — | Pending | Jul 08, 2022 |
| 17825244 | ANTI-IDIOTYPIC ANTIBODIES AGAINST ANTI-CD79B ANTIBODIES | GUSTILO, ESTELLA M | 1646 | §103§112Other | Non-Final OA | 147d overdue | Pending | May 26, 2022 |
| 17767263 | MATERIALS AND METHODS FOR MASS SPECTROMETRIC PROTEIN ANALYSIS | SIMMONS, VALERIE MICHELLE | 1758 | §103 | Non-Final OA | 9d | Pending | Apr 07, 2022 |
| 17691050 | Combination Therapies Comprising Daratumumab, Bortezomib, Thalidomide and Dexamethasone and Their Uses | ALSOMAIRY, SARAH ABDOALATIF | 1646 | §103 | Final Rejection | 27d | Pending | Mar 09, 2022 |
| 17630706 | MATERIALS AND METHODS FOR POLYMERIC ANTIBODY RECEPTOR TARGETING | JOHANSEN, PETER N. | 1600 | DP | Non-Final OA | — | Pending | Jan 27, 2022 |
| 17615959 | ANTI-TNF ANTIBODIES, COMPOSITIONS, AND METHODS FOR THE TREATMENT OF ACTIVE ANKYLOSING SPONDYLITIS | XIE, XIAOZHEN | 1674 | §103 | Non-Final OA | 20d | Pending | Dec 02, 2021 |
| 17615949 | ANTI-TNF ANTIBODY COMPOSITIONS, AND METHODS FOR THE TREATMENT OF PSORIATIC ARTHRITIS | DAHLE, CHUN WU | 1641 | DP | Final Rejection | — | Pending | Dec 02, 2021 |
| 17412346 | Stable Formulations Comprising A Bispecific EGFR/C-Met Antibody | BERHANE, SELAM | 1675 | §103 | Non-Final OA | — | Pending | Aug 26, 2021 |
| 17417022 | Beta-Galactosidase Alpha Peptide as a Non-Antibiotic Selection Marker and Uses Thereof | WHITEMAN, BRIAN A | 1600 | §103 | Final Rejection | — | Pending | Jun 21, 2021 |
| 17235974 | NEUROLOGIC TOXICITY ASSESSMENT METHODS AND SYSTEMS FOR DOCUMENTING CHANGES IN HANDWRITING | ROBERTS, ANNA L | 3791 | §101§102 | Final Rejection | 164d overdue | Pending | Apr 21, 2021 |
| 17182429 | CAPACITY OPTIMIZATION ACROSS DISTRIBUTED MANUFACTURING SYSTEMS | LEE, PO HAN | 3623 | §101 | Final Rejection | 34d | Pending | Feb 23, 2021 |
| 17174590 | NEOANTIGENS EXPRESSED IN MULTIPLE MYELOMA AND THEIR USES | EDGINGTONGIORDANO, FRANCESCA | 1643 | §103 | Final Rejection | — | Pending | Feb 12, 2021 |
| 17005858 | B-CELL MATURATION COMPLEX CAR T CONSTRUCT AND PRIMERS | HANEY, AMANDA MARIE | 1682 | §103§112 | Non-Final OA | 23d | Pending | Aug 28, 2020 |
| 16797301 | Methods of Treating Newly Diagnosed Multiple Myeloma with a Combination of An Antibody that Specifically Binds CD38, Lenalidomide and Dexamethasone | SANG, HONG | 1646 | §103 | Final Rejection | 4d overdue | Pending | Feb 21, 2020 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial